Pharmaceutical composition for improving health, cure abnormalities and degenerative disease, achieve anti-aging effect of therapy and therapeutic effect on mammals and method thereof
A pharmaceutical composition of the present invention is used for improving health, cure abnormalities and degenerative disease; achieve anti-aging effect of therapy and therapeutic effect on mammals. The pharmaceutical composition includes a pharmaceutical carrier and an isotope selective ingredient including at least one of a chemical element and a chemical compound containing the chemical element whereby isotope distribution in the at least one of the chemical element and the chemical compound containing the chemical element is different from natural distribution of at least one of isotopes wherein the part of selected isotope of the chemical element ranges from 0 to 100%. A method of the present invention uses the inventive pharmaceutical composition to improve health, cure abnormalities and degenerative disease and achieve therapeutic effect on mammals.
1. A method of treating a patient having a solid tumor comprising the steps of: administering a first therapeutic composition comprising a therapeutically effective amount of one or more of 39 K-enriched potassium, 24 Mg-enriched magnesium, 64 Zn-enriched zinc, 85 Rb-enriched rubidium, and 28 Si-enriched silicon, present as an element or in the form of a pharmaceutically acceptable salt, compound or complex thereof, and at least one excipient; wherein the 39 K-enriched potassium is at least about 98% 39 K, the 24 Mg enriched magnesium is at least about 95% Mg, the 64 Zn-enriched zinc is at least about 90% 64 Zn, the 85 Rb-enriched rubidium is at least about 90% 85 Rb, and the 28 Si-enriched silicon is at least about 95% 28 Si to the patient, surgically removing the solid tumor from the patient, and administering a second therapeutic composition comprising a therapeutically effective amount of one or more of 39 K-enriched potassium, 24 Mg-enriched magnesium, 64 Zn-enriched zinc, 85 Rb-enriched rubidium, and 28 Si-enriched silicon, present as an element or in the form of a pharmaceutically acceptable salt, compound or complex thereof, and at least one excipient; wherein the 39 K-enriched potassium is at least about 98% 39 K, the 24 Mg-enriched magnesium is at least about 95% 24 Mg, the 64 Zn-enriched zinc is at least about 90% 64 Zn, the 85 Rb-enriched rubidium is at least about 90% 85 Rb, and the 28 Si-enriched silicon is at least about 95% 28 Si to the patient.
2. The method of claim 1 , wherein the first or the second composition contains 39 K-enriched potassium and wherein the composition contains between 1 g and 14.5 g of 39 K.
3. The method of claim 1 , wherein the first or the second composition contains 24 Mg-enriched magnesium.
4. The method of claim 3 , wherein the first or the second composition contains between 10 mg and 13 g of 24 Mg.
5. The method of claim 1 , wherein the first or the second composition contains 64 Zn-enriched zinc.
6. The method of claim 1 , wherein the first or the second composition contains between 0.6 mg and 330 mg of 64 Zn.
7. The method of claim 1 , wherein the first or the second composition contains 64 Zn-enriched zinc and the 64 Zn-enriched zinc is at least 90% 64 Zn, wherein the composition contains between 0.6 mg and 330 mg of 64 Zn, and wherein the 64 Zn-enriched zinc is present as a chelate of an amino acid.
8. The method of claim 1 , wherein the first or the second composition contains 85 Rb-enriched rubidium.
9. The method of claim 8 , wherein the first or the composition contains between 0.3 mg and 60 mg of 85 Rb.
10. The method of claim 1 , wherein the first or the second composition contains 28 Si-enriched silicon.
11. The method of claim 10 , wherein the first or the second composition contains between 3.3 mg and 300 mg of 28 Si.